Results 1 to 10 of about 3,715,994 (387)

The cytokine receptor CRLF3 is a human neuroprotective EV-3 (Epo) receptor [PDF]

open access: yesFrontiers in Molecular Neuroscience, 2023
The evolutionary conserved orphan cytokine receptor-like factor 3 (CRLF3) has been implicated in human disease, vertebrate hematopoiesis and insect neuroprotection.
Debbra Y. Knorr   +10 more
doaj   +2 more sources

Cytokine Receptor-Like Factor 3 (CRLF3) Contributes to Early Zebrafish Hematopoiesis [PDF]

open access: yesFrontiers in Immunology, 2022
Cytokine receptor-like factor 3 (CRLF3) is an ancient protein conserved across metazoans that contains an archetypal cytokine receptor homology domain (CHD).
Tarannum Taznin   +6 more
doaj   +2 more sources

In Situ Identification of Both IL-4 and IL-10 Cytokine–Receptor Interactions during Tissue Regeneration [PDF]

open access: yesCells, 2023
Cytokines secreted by individual immune cells regulate tissue regeneration and allow communication between various cell types. Cytokines bind to cognate receptors and trigger the healing process.
Krisztina Nikovics   +6 more
doaj   +2 more sources

Mapping Determinants of Cytokine Signaling via Protein Engineering [PDF]

open access: yesFrontiers in Immunology, 2018
Cytokines comprise a large family of secreted ligands that are critical for the regulation of immune homeostasis. Cytokines initiate signaling via dimerization or oligomerization of the cognate receptor subunits, triggering the activation of the Janus ...
Claire Gorby   +3 more
doaj   +5 more sources

Cytokine-Leukotriene Receptor Interactions [PDF]

open access: yesThe Scientific World Journal, 2007
Biochemical and pharmacological studies have identified the structure of leukotrienes, the pathways that lead to their synthesis, and the signaling events they trigger when they interact with their cognate receptors.
Marek Rola-Pleszczynski, Jana Stankova
doaj   +3 more sources

Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cells. [PDF]

open access: goldCell Rep Med
Yoshikawa T   +11 more
europepmc   +2 more sources

Targeting IFN activity to both B cells and plasmacytoid dendritic cells induces a robust tolerogenic response and protection against EAE

open access: yesScientific Reports, 2021
Type I Interferon (IFN) was the very first drug approved for the treatment of Multiple Sclerosis (MS), and is still frequently used as a first line therapy. However, systemic IFN also causes considerable side effects, affecting therapy adherence and dose
Anje Cauwels   +9 more
doaj   +1 more source

Pro-inflammatory signaling by IL-10 and IL-22: bad habit stirred up by interferons? [PDF]

open access: yes, 2013
Interleukin (IL)-10 and IL-22 are key members of the IL-10 cytokine family that share characteristic properties such as defined structural features, usage of IL-10R2 as one receptor chain, and activation of signal transducer and activator of ...
Mühl, Heiko
core   +9 more sources

Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers

open access: yeseLife, 2023
Dimerization of the thrombopoietin receptor (TpoR) is necessary for receptor activation and downstream signaling through activated Janus kinase 2. We have shown previously that different orientations of the transmembrane (TM) helices within a receptor ...
Jean-Philippe Defour   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy